Indivior Pharmaceuticals, Inc. (INDV)
NASDAQ
Closed
Oct 8, 2026
Day's Range
34.8552 wk Range
22.95Overview - INDV - Indivior Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
4.46B
P/E (Trailing)
‪12.68‬
P/E (Forward)
‪7.24‬
PEG Ratio
‪0.02‬
Price / Sales (TTM)
‪3.13‬
Price / Book
‪-20.34‬
EV / EBITDA
‪7.74‬
Profitability
Gross Margin
‪85.42%‬
Profit Margin
‪26.74%‬
Operating Margin
‪46.93%‬
Return on Assets
‪26.39%‬
Return on Equity
‪-212.12%‬
Ownership
Shares Outstanding
118.00M
Float
115.80M
Short % of Shares Outstanding
‪11.25%‬
Held by Insiders
‪1.80%‬
Held by Institutions
‪99.13%‬
Price stats
Beta
‪1.11‬
50-Day Avg
‪36.92‬
200-Day Avg
‪35.73‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
4 analysts
Average price target
‪$ 49.00‬Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - INDV - Indivior Pharmaceuticals, Inc.
Peers - INDV - Indivior Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- INDVNASDAQIndivior Pharmaceuticals, Inc.4.21BMarket Cap+36.35%52-week change12.68P/E (Trailing)‪26.74%‬Profit Margin
- NBIXNASDAQNeurocrine Biosciences, Inc.14.55BMarket Cap+2.62%52-week change20.93P/E (Trailing)‪20.91%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals, Inc.7.07BMarket Cap+48.03%52-week change42.29P/E (Trailing)‪5.04%‬Profit Margin
- ALKSNASDAQAlkermes plc7.00BMarket Cap+25.77%52-week change109.87P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings Inc.6.52BMarket Cap+47.28%52-week change23.91P/E (Trailing)‪17.69%‬Profit Margin
- KNSANASDAQKiniksa Pharmaceuticals International, plc Class A Ordinary Shares5.83BMarket Cap+49.48%52-week change76.56P/E (Trailing)‪9.59%‬Profit Margin
- DIODNASDAQDiodes Incorporated4.43BMarket Cap+44.79%52-week change51.08P/E (Trailing)‪5.26%‬Profit Margin
Profile Summary - INDV - Indivior Pharmaceuticals, Inc.
About
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on medicines for opioid use disorder and related substance use disorders. The company develops, manufactures, and markets buprenorphine-based prescription treatments designed to support recovery and long-term disease management in clinical…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
